Bone Biologics CorpBBLG
Price$0.47

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value Insufficient data for a value estimatebased on filings through 31 Mar 2026
Market Price $0.47Price as of 1 Oct 2026
Data confidenceNot applicable

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 5.0%/yr (balance of the path).5.0% per year
Years 6–10: glide to demonstrated growth own history 68.9%, capped at 20%
Per-year rates
Yr 65.0%Yr 75.0%Yr 85.0%Yr 95.0%Yr 105.0%
5.0% → 5.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 114.8%Yr 124.6%Yr 134.4%Yr 144.2%Yr 154.0%Yr 163.8%Yr 173.6%Yr 183.4%Yr 193.2%Yr 203.0%
5.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)68.9%
Discount rate (cost of equity) 8.1%
Volatility vs market (adjusted beta)0.71

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetBone Biologics CorpBBLGHealth Care
Valuation
P/E—
P/S—
P/B0.2×
EV / Revenue—
EV / EBITDA—
Profitability
Gross margin—
Operating margin—
Net margin—
FCF margin—
Returns
ROE-61.2%
ROA-57.4%
ROIC—
Growth
Revenue growth (YoY)—
5-yr fwd EPS growth—
Financial strength
Debt / Equity0.00×
Current ratio—
Altman Z-Score—
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.